^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
CANCER:

Astrocytoma

Related cancers:
1year
MYBL1 (MYB Proto-Oncogene Like 1)
1year
FGFR1 (Fibroblast growth factor receptor 1)
|
FGFR1 mutation
|
Pemazyre (pemigatinib)
over1year
FGFR1 (Fibroblast growth factor receptor 1)
|
FGFR1 mutation
|
Pemazyre (pemigatinib)
over1year
IDH1 (Isocitrate dehydrogenase (NADP(+)) 1)
|
IDH1 mutation
over1year
BRAF (B-raf proto-oncogene) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A)
|
BRAF mutation • CDKN2A deletion • CDKN2A mutation
over1year
FGFR1 (Fibroblast growth factor receptor 1)
|
FGFR1 mutation
|
Pemazyre (pemigatinib)
almost2years
FGFR1 (Fibroblast growth factor receptor 1)
|
FGFR1 mutation
|
Pemazyre (pemigatinib)
almost2years
EGFR (Epidermal growth factor receptor) • TERT (Telomerase Reverse Transcriptase) • MVP (Major Vault Protein)
|
EGFR mutation • TERT mutation • IDH wild-type
almost2years
FGFR1 (Fibroblast growth factor receptor 1)
|
FGFR1 mutation
|
Pemazyre (pemigatinib)
almost2years
FGFR1 (Fibroblast growth factor receptor 1)
|
FGFR1 mutation
|
Pemazyre (pemigatinib)
almost2years
FGFR1 (Fibroblast growth factor receptor 1)
|
FGFR1 mutation
|
Pemazyre (pemigatinib)
almost2years
FGFR1 (Fibroblast growth factor receptor 1)
|
FGFR1 mutation
|
Pemazyre (pemigatinib)
2years
Next-generation sequencing • Epigenetic controller
|
CDKN2A (Cyclin Dependent Kinase Inhibitor 2A)
|
CDKN2A deletion
3years
CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B)
|
CDKN2A deletion
over3years
BRAF (B-raf proto-oncogene) • KIAA1549
|
KIAA1549-BRAF fusion • BRAF fusion